Core Viewpoint - The article discusses the expertise of Sensor Unlimited in financial economics, particularly in the mortgage market, commercial market, and banking industry, highlighting her contributions to asset allocation and ETFs [2] Group 1: Company Overview - Sensor Unlimited has a PhD in financial economics and has spent a decade covering various financial sectors, including mortgages and banking [2] - The company offers two model portfolios aimed at different investment strategies: one for short-term survival and another for aggressive long-term growth [2] Group 2: Services Offered - The investment group Envision Early Retirement, led by Sensor Unlimited, provides solutions for generating high income and growth with managed risks through dynamic asset allocation [2] - Services include direct access via chat for idea discussions, monthly updates on holdings, tax discussions, and ticker critiques upon request [2]

In 1996, 60 Minutes spoke with then-FDA commissioner David Kessler about his investigation into the tobacco industry. Dr. Kessler presented Lesley Stahl with his evidence that tobacco companies had manipulated nicotine levels to hook consumers. "60 Minutes" is the most successful television broadcast in history. Offering hard-hitting investigative reports, interviews, feature segments and profiles of people in the news, the broadcast began in 1968 and is still a hit, over 50 seasons later, regularly making ...

Group 1 - The article emphasizes the benefits of a dividend-focused value investment strategy, highlighting capital preservation and steadily growing income as key components [1] - The author discusses a diversified dividend stock portfolio that prioritizes high-quality value stocks, which are expected to provide meaningful growth and long-term safety [1] Group 2 - The author has disclosed a beneficial long position in shares of specific companies, indicating a personal investment interest in PM, MO, and BTAFF [2] - The article is presented as a personal opinion and does not involve compensation from any companies mentioned, reinforcing the independence of the analysis [2]

Group 1: Coca-Cola - Coca-Cola is the world's largest beverage company, diversifying its portfolio to include bottled water, fruit juices, teas, sports drinks, energy drinks, coffee, and non-carbonated drinks to counter declining soda consumption [2][4] - The company operates a capital-light business model, selling concentrates and syrups while independent bottling partners handle production, allowing for stable margins and strong cash flow to support a forward yield of 2.6% [3][4] - Coca-Cola's organic revenue rose 5% in 2025, with expectations of 4%-5% growth in 2026, and it is currently valued at 25 times forward earnings, making it a reliable investment in a volatile market [4] Group 2: Altria - Altria, the largest tobacco company in America, faces challenges from declining U.S. smoking rates but mitigates this by raising prices, cutting costs, and repurchasing shares to enhance EPS and support dividends [5][7] - The company is shifting towards smoke-free products, aiming for at least $5 billion in smoke-free revenues by 2028, bolstered by its acquisition of e-cigarette leader NJOY in 2023 [6][7] - Altria offers a forward yield of 6.3% and has raised its dividend 60 times over the past 56 years, with adjusted EPS growth of 4% in 2025 and anticipated growth of 2.5%-5.5% in 2026, trading at 12 times forward earnings [7]

Core Insights - Altria Group, Inc. demonstrated resilience in its fourth-quarter 2025 performance, maintaining earnings growth despite ongoing cigarette volume declines and regulatory challenges [1][9] - The company has effectively utilized pricing power, disciplined cost management, and strategic investments in smoke-free alternatives to protect margins [1][21] Stock Performance - Following the fourth-quarter results released on January 29, 2026, Altria's shares increased by 12%, indicating improved investor confidence in its earnings stability [2] - Over the past three months, Altria's shares rose by 15.9%, outperforming the Zacks Consumer Staples sector's 12.1% and the S&P 500's 3.7% [3] - Compared to peers, Altria's performance was solid, with notable gains from Turning Point Brands (31.9%), Philip Morris (21.8%), and British American Tobacco (11.3%) [4] Financial Results - Altria's fourth-quarter adjusted earnings remained flat year-over-year at $1.30, with net revenues declining by 2.1% to $5.8 billion, primarily due to lower revenues in the smokeable products segment [9][10] - Domestic cigarette shipment volumes fell by 7.9% in the quarter, contributing to revenue pressures, but adjusted operating companies income (OCI) remained resilient at $2.64 billion with margins at 60.4% [11] - The Oral Tobacco Products segment also contributed positively, with adjusted OCI declining slightly to $440 million but showing growth in the modern oral portfolio [12] Capital Returns - Altria paid $7 billion in dividends in 2025, including $1.8 billion in the fourth quarter, showcasing strong cash generation capabilities [13] - The company repurchased 4.8 million shares for $288 million in the fourth quarter, with a total of 17.1 million shares repurchased for approximately $1 billion in the full year [14] 2026 Outlook - Management expects 2026 adjusted EPS in the range of $5.56 to $5.72, indicating growth of 2.5% to 5.5% from 2025 [15] - The outlook is based on anticipated pricing strength, cost discipline, and planned investments in smoke-free products, with capital expenditures projected between $300 million and $375 million [16] Valuation - Altria is currently trading at a forward P/E ratio of 11.98X, significantly lower than the industry average of 16.07X and the S&P 500's average of 22.9X, making it attractive for value-focused investors [17] - Compared to peers, Altria's valuation is appealing, as Philip Morris and Turning Point Brands trade at higher multiples of 22.39X and 31.65X, respectively [18] Investor Sentiment - The post-earnings rally reflects growing recognition of Altria's consistent execution, resilient margins, and dependable cash-return framework [21] - Despite ongoing structural challenges, the company's ability to offset pressures through pricing and cost management enhances its appeal for long-term, income-oriented investors [21]

Core Insights - Service Corporation International (SCI) reported strong fourth-quarter 2025 results, with both revenue and earnings increasing year over year, driven by growth in funeral and cemetery segments, higher gross profit, and disciplined capital management [1][9] Financial Performance - Adjusted earnings per share (EPS) for Q4 2025 were $1.14, an 8% increase from $1.06 in the same quarter last year, matching the Zacks Consensus Estimate [2] - Total revenues reached $1,111.5 million, a 2% increase from $1,093.0 million year over year, although slightly below the Zacks Consensus Estimate of $1,119 million [2] - Gross profit rose by 1.9% to $311.7 million, maintaining a gross margin of 28% [2] Segment Analysis - **Funeral Segment**: - Total funeral revenues increased to $600.6 million from $587.7 million in Q4 2024, with gross profit rising to $126.2 million [4] - Average revenue per service grew by 3.3% to $5,880 [4] - Comparable funeral revenues rose 0.5% to $580.4 million, with comparable preneed funeral sales production up 11% to $294.1 million [5] - **Cemetery Segment**: - Total cemetery revenues increased to $510.9 million from $505.3 million in Q4 2024, with gross profit up 2.6% to $185.5 million [6] - Comparable cemetery revenues rose 0.9% to $508.3 million, driven by higher other revenues [7] Operating Income and Expenses - Operating income increased by 5.1% to $275.6 million from $262.2 million in the prior-year quarter [3] - Corporate general and administrative expenses were $33.7 million, significantly higher than $15.0 million in the prior-year period, primarily due to a reduction in legal reserves in the previous year [3] Financial Health and Outlook - At the end of 2025, SCI had $243.6 million in cash and cash equivalents, up from $218.8 million at the end of 2024, with long-term debt totaling $5.1 billion [10] - For 2026, SCI expects diluted EPS in the range of $4.05-$4.35, indicating growth within its long-term target range of 8-12% [13] - Projected net cash provided by operating activities for 2026 is between $1,005 million and $1,065 million after cash taxes [14]

BAT warned South Africa’s government for years that it would be forced to end production there if illegal cigarette sales weren’t stamped out, according to the CEO https://t.co/GkKnJJKxX3 ...

Core Viewpoint - The latest analysis on British American Tobacco p.l.c. has shifted from Buy and Strong Buy ratings to a Sell recommendation due to concerns over low growth in the New Category and competition from Philip Morris [1]. Company Analysis - British American Tobacco has experienced a decline in growth prospects, particularly in its New Category segment, which is critical for future revenue generation [1]. - The competitive landscape is intensifying, especially with Philip Morris making significant strides in market share and product innovation [1]. Industry Context - The tobacco industry is facing challenges related to evolving consumer preferences and regulatory pressures, which are impacting growth trajectories for traditional tobacco companies [1].

Core Viewpoint - A potential U.S. move to block imports of certain disposable vapes could significantly reduce the unregulated e-cigarette market by up to one-third, although any impact is not expected before 2027 [1] Group 1: Market Impact - British American Tobacco (BAT) estimates that unregulated devices account for approximately 70% of U.S. e-cigarette sales, affecting both its vaping and traditional tobacco businesses [2] - CEO Tadeu Marroco indicated that a block could lead to a decline in market sales to below 50%, equating to a reduction of roughly one-third [4] - The long supply chain and large inventories for these devices may delay the impact of any potential import block [4] Group 2: Legal and Regulatory Developments - BAT has two active cases at the U.S. International Trade Commission (ITC) aimed at blocking imports of unregulated devices [2] - An ITC judge previously ruled in favor of BAT in a patent dispute, recommending a general exclusion order to block disposable vapes that infringe its patents [3] - A full ITC determination is expected in March, followed by a 60-day presidential review [3] Group 3: Future Regulatory Changes - There is speculation that the U.S. Food and Drug Administration (FDA) may initiate a program to test new approaches to vapes, potentially including flavored options [5] - The FDA has been working to expedite or streamline its processes for new nicotine product applications after years of rejecting most [5]

Core Viewpoint - A potential U.S. move to block imports of certain disposable vapes could reduce the unregulated e-cigarette market by up to one-third, according to British American Tobacco's CEO, although any significant impact is not expected before 2027 [1]. Group 1: Market Impact - The unregulated e-cigarette devices account for approximately 70% of U.S. e-cigarette sales, adversely affecting both vape and traditional tobacco businesses [1]. - A block on imports could lead to a decline in industry sales to below 50%, equating to a reduction of roughly one-third [1]. - The CEO indicated that the scale of the impact is difficult to predict due to existing supply chains and large inventories that would delay effects [1]. Group 2: Regulatory Developments - British American Tobacco has two active cases at the U.S. International Trade Commission (ITC) aimed at blocking imports of unregulated devices [1]. - An ITC judge previously ruled in favor of BAT in a patent dispute, recommending a general exclusion order against disposable vapes infringing its patents [1]. - A full ITC determination is expected in March, followed by a 60-day presidential review [1]. Group 3: Future Considerations - The CEO suggested that the U.S. Food and Drug Administration (FDA) may initiate a program to explore different approaches to vapes, potentially including flavored options [1]. - The FDA has been looking to expedite or streamline its processes after years of rejecting most applications for new nicotine products [1].